Baker Tilly Wealth Management LLC Has $1.26 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Baker Tilly Wealth Management LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 25.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,499 shares of the medical instruments supplier’s stock after purchasing an additional 1,123 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,260,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Czech National Bank raised its stake in Becton, Dickinson and Company by 5.2% during the 1st quarter. Czech National Bank now owns 65,950 shares of the medical instruments supplier’s stock worth $15,107,000 after buying an additional 3,280 shares during the period. Rhumbline Advisers increased its holdings in shares of Becton, Dickinson and Company by 2.5% in the first quarter. Rhumbline Advisers now owns 507,280 shares of the medical instruments supplier’s stock worth $116,197,000 after acquiring an additional 12,204 shares in the last quarter. Marion Wealth Management raised its position in shares of Becton, Dickinson and Company by 5.8% during the first quarter. Marion Wealth Management now owns 11,459 shares of the medical instruments supplier’s stock worth $2,625,000 after purchasing an additional 631 shares during the period. Somerset Trust Co lifted its holdings in shares of Becton, Dickinson and Company by 4.5% during the 1st quarter. Somerset Trust Co now owns 16,202 shares of the medical instruments supplier’s stock valued at $3,711,000 after purchasing an additional 705 shares in the last quarter. Finally, Summit Global Investments acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $790,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.7%

Shares of BDX stock opened at $172.53 on Monday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a market cap of $49.45 billion, a price-to-earnings ratio of 28.66, a PEG ratio of 1.63 and a beta of 0.31. The firm’s 50-day moving average is $192.64 and its 200-day moving average is $216.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the prior year, the company earned $3.17 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.41%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at $964,107.36. This represents a 8.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Richard Byrd sold 459 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. The trade was a 6.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,878 shares of company stock worth $636,393 over the last ninety days. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on BDX. Barclays dropped their target price on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a report on Monday, April 7th. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. The Goldman Sachs Group cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price for the company. in a report on Friday, May 2nd. Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and decreased their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Bank of America cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $221.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.